Seaside Therapeutics Secures $30M to Fight Autism
Seaside Therapeutics has secured $30 million in funding from a private, unnamed family investment firm committed to finding treatments for autism and Fragile X syndrome.
cortex pharmaceuticals
FDA Approves First Monthly Atypical Antipsychotic for Schizophrenia
The U.S. Food and Drug Administration has approved Janssen Pharmaceuticals’ Invega Sustenna for acute and maintenance treatment of schizophrenia.